Description of the PODA-3D Project

The PODA-3D project aims to revolutionize drug testing methods by harnessing the potential of three-dimensional (3D) cell models, such as spheroids and organoids. These models represent a breakthrough in pharmaceutical research due to their ability to more accurately simulate human physiology and disease mechanisms compared to traditional two-dimensional methods. However, their adoption has been hindered by the complexity of their three-dimensional structure, which introduces variability and challenges in reproducibility. This project seeks to overcome these obstacles by developing an advanced platform that standardizes and improves the reliability of drug testing.

Project Objectives

The core goal of PODA-3D is to design and implement an intelligent scoring system based on multiple parameters for 3D tumor cell models, significantly reducing the uncertainty associated with critical metrics such as IC50 values (a key indicator of drug potency). By leveraging CellDynamics’ innovative technology—which allows for multiparametric quantification of spheroids, including size, weight, mass density, and stiffness—the project aims to address key challenges in 3D model-based testing. Additional biophysical parameters, such as sphericity and shape factors, will further help to minimize the intrinsic variability of these models.

Initially, the project will focus on spheroids derived from breast cancer and glioblastoma, addressing therapeutic challenges across diverse pathological contexts. The platform will integrate automated liquid handling systems to reduce manual errors, combining biology, technology, and data science in a multidisciplinary approach.

Expected Results

The project is expected to achieve the following results:

·       Standardization and Reliability in Testing: Development of an advanced scoring system to enhance the reproducibility and reliability of drug testing using 3D cell models.

·       Reduction of Variability: Mitigation of inconsistencies in results through the inclusion of advanced biophysical parameters, ensuring greater precision in analyses.

·       Process Automation: Creation of certified prototypes and advanced software for automated testing, boosting efficiency and shortening drug development timelines.

·       Ethical and Environmental Impact: Promotion of alternatives to animal testing in alignment with EU 3R regulations, while accelerating the transition to personalized medicine.

Overall Impact

The PODA-3D project represents a significant step forward for the future of personalized medicine and healthcare technology. Its industrial implementation promises to lower costs and accelerate drug development, fostering more effective and targeted therapies for patients. Additionally, it positions Italian research at the forefront of biomedical and technological innovation, paving the way for breakthroughs in precision medicine and sustainable scientific practices.